Ahmad Kiadaliri Aliasghar, Bastani Peivand, Ibrahimipour Hossein
Division of Health Economics, Department of Clinical Sciences, Lund University, Malmo, Sweden.
Asian Pac J Cancer Prev. 2012;13(3):941-4. doi: 10.7314/apjcp.2012.13.3.941.
The aim of current study was to evaluate the changes of health-related quality of life (HRQoL) and its clinical, demographic and socioeconomic determinants during chemotherapy and 4 months follow-up in women with breast cancer using a repeated measures framework.
A double blind cohort study was performed in 100 breast cancer patients given fluorouracil, doxorubicin and cyclophosphamide (FAC) or docetaxel, doxorubicin, cyclophosphamide (TAC) in south of Iran. HRQoL was assessed at baseline, end of chemotherapy and four months thereafter using the QLQ-C30 questionnaire from European Organization for Research and Treatment of Cancer (EORTC). Generalized estimating equations (GEE) was applied for statistical analysis.
The mean of age at baseline was 48.5±10.6. 70% and 14% of patients were married and smokers, respectively, and 20% suffered from another disease besides breast cancer. The results of GEE showed that after control for baseline scores, the HRQoL significantly improved over time. Although, the patients in FAC group had higher scores than the TAC group, the differences also diminished over time. Smoking, marital status and having child affected some scales of HRQoL. None of other variables were significantly related to HRQoL.
Although patients in TAC groups had lower level of HRQoL over 8 months follow up, they experienced faster improvement than the FAC group. This implies that in long-term, improvements in TAC group are higher than FAC. Having children was positively correlated with HRQoL. Generally, there were no demographic and socio-economic differences in HRQoL in these patients between the chemotherapeutic regimens.
本研究旨在采用重复测量框架评估乳腺癌女性患者在化疗期间及4个月随访期内健康相关生活质量（HRQoL）的变化及其临床、人口统计学和社会经济决定因素。
在伊朗南部对100例接受氟尿嘧啶、多柔比星和环磷酰胺（FAC）或多西他赛、多柔比星、环磷酰胺（TAC）治疗的乳腺癌患者进行了一项双盲队列研究。使用欧洲癌症研究与治疗组织（EORTC）的QLQ-C30问卷在基线、化疗结束时及之后4个月评估HRQoL。采用广义估计方程（GEE）进行统计分析。
基线时的平均年龄为48.5±10.6岁。分别有70%和14%的患者已婚和吸烟，20%除乳腺癌外还患有其他疾病。GEE结果显示，在控制基线评分后，HRQoL随时间显著改善。虽然FAC组患者的得分高于TAC组，但随着时间推移差异也逐渐减小。吸烟、婚姻状况和育有子女影响了HRQoL的某些量表。其他变量均与HRQoL无显著相关性。
虽然在8个月的随访期内TAC组患者的HRQoL水平较低，但他们比FAC组改善得更快。这意味着从长期来看，TAC组的改善程度高于FAC组。育有子女与HRQoL呈正相关。总体而言，这些患者在不同化疗方案之间的HRQoL在人口统计学和社会经济方面没有差异。
